Johnson & Johnson is taking legal action against the U.S. Department of Health and Human Services (HHS) in a bid to protect its proposed drug rebate plan. The company claims that HHS is obstructing its attempt to sell its treatments, including Stelara for psoriasis and Xarelto for blood thinning, to hospitals at full price before applying drug rebates.
The pharmaceutical giant filed the lawsuit in Washington, accusing certain healthcare providers of exploiting the federal 340B drug-discount program for profit. This program is meant to offer discounted drugs to eligible facilities serving low-income and uninsured patients, but J&J argues that some hospitals are misusing the system.
J&J’s rebate model aims to bring greater transparency and ensure that vulnerable patients can still access necessary medications. The company argues that its plan aligns with the original goals of the 340B program, which requires drug manufacturers to offer upfront discounts to participating healthcare providers in exchange for eligibility for government health insurance funds.
The case highlights the ongoing legal battles over the 340B program, which has faced scrutiny for being misused by entities outside its intended scope. J&J is requesting a court ruling that would declare its rebate plan lawful and prevent HHS from interfering with the initiative.
As the legal wrangling continues, the 340B program’s future remains a point of contention, with drugmakers and healthcare providers at odds over the program’s impact and effectiveness in delivering affordable healthcare to those who need it most.
